Clinical trials: Immunoglobulin
Multiple Myeloma
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether CM336, a BCMA/CD3 bispecific antibody, in combination with daratumumab and lenalidomide can induce deep and durable responses in adults with transplant-ineligible newly…
- Trial name
- CAREMM-010 (NCT07830485)
- Testing
- CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
- Trial name
- NCT03430843
- Testing
- Tislelizumab, Paclitaxel, Docetaxel
- Where
- 104 sites in United States, Belgium and 9 more
- Volunteers
- 512 people
- Sponsor
- BeiGene
Relapsed or Refractory Multiple Myeloma
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or…
- Trial name
- MajesTEC-9 (NCT05572515)
- Testing
- Teclistamab, Pomalidomide, Bortezomib
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 614 people
- Sponsor
- Janssen Research & Development, LLC
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06287944
- Testing
- Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Parkinson's Disease
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene.
- Trial name
- PreCoDe (NCT07055087)
- Testing
- Prasinezumab, Sodium Chloride
- Where
- 11 sites in France, Germany and 5 more
- Volunteers
- 120 people
- Sponsor
- University Hospital Tuebingen
Demyelinating Diseases, Paraproteinemias
Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demylinating Polyneuropathy (CIDP) is an autoimmune condition affecting the nervous system. Researchers believe the immune system begins attacking the cells covering nerves called myelin.
- Trial name
- NCT00001287
- Testing
- intravenous immunoglobulin (IVIg)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Hepatitis A, Hepatitis B
Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult
This study will evaluate the persistence of the immune response to HAV (hepatitis A virus) antigens and HBs (hepatitis B surface) antigens in healthy adults previously vaccinated with Twinrix Adult in the primary study, HAB-032…
- Trial name
- NCT01037114
- Testing
- Blood sampling, Engerix-B, Havrix
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Malignant Glioma, Anaplastic Astrocytomas
AMG 595 First-in-Human in Recurrent Gliomas
This is an open-label, sequential dose exploration study of single agent AMG 595 administered in subjects with recurrent glioblastoma multiforme (GBM) and/or anaplastic astrocytomas (AA).
- Conditions
- Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme
- Trial name
- NCT01475006
- Testing
- AMG 595
- Where
- 4 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Amgen
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Healthy
FCM Analysis GR in Steroid-Treatment Patients
Monitoring the GR with a GR-MoAb and FITC-Dex probes by FCM would be useful and convenient in determination GR before the steroid treatment in clinical, especially in steroid resistant states, in order to design more efficient…
- Trial name
- NCT00600652
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Resectable Pancreatic Adenocarcinoma
Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer
This study intends to design the prospective, exploratory, single center clinical study, using targeted EGFR fluorescence imaging agent (anti-EGFR-IR800CW) and fluorescent navigation technology, in its lymph node tracing…
- Trial name
- CISPD-6 (NCT06168552)
- Testing
- Injection of fluorescent developer (anti-EGFR-IR800CW)
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Transfusion Transmitted Babesiosis
Babesia Testing in Blood Donors
Both prospective and retrospective (look back) study of blood donors for laboratory evidence of babesia microti infection. Two laboratory methodologies will be utilized: 1.
- Trial name
- NCT01528449
- Testing
- B.microti diagnostic blood tests
- Where
- United States
- Volunteers
- 90,116 people, healthy volunteers welcome
- Sponsor
- Imugen
Advanced Solid Tumors, Melanoma
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
- Trial name
- NCT04172454
- Testing
- AK104
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Covid19
Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.
MAD0004J08, the experimental drug, is a potent neutralizing IgG1 monoclonal antibody (mAb) targeting the spike protein of SARS-CoV-2. MAD0004J08 blocks viral attachment and entry into human cells and neutralizes the virus.
- Trial name
- NCT04952805
- Testing
- MAD0004J08
- Where
- 14 sites in Italy
- Volunteers
- 800 people
- Sponsor
- Toscana Life Sciences Sviluppo s.r.l.
Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events.
- Trial name
- MERCURION-IPF (NCT07299695)
- Testing
- Intravenous immunoglobulin (IVIG), Usual treatment
- Where
- Greece
- Volunteers
- 196 people
- Sponsor
- Argyrios Tzouvelekis
Unresectable Intrahepatic Cholangiocarcinoma
Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to learn about the combined therapy using drug-eluting bead-transarterial chemoembolization (D-TACE), gemcitabine (Gem) and cisplatin (Cis) chemotherapy, and PD-1 antibody in patients with…
- Trial name
- NCT05738057
- Testing
- Camrelizumab, Gemcitabine Injection, Cisplatin injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Hua Li
Multiple Myeloma
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed (the return of a disease or the signs and symptoms of a disease after a period of improvement.) or refractory (cancer…
- Trial name
- NCT00402181
- Testing
- Siltuximab, Dexamethasone
- Where
- 13 sites in United States, Netherlands
- Volunteers
- 53 people
- Sponsor
- Centocor, Inc.
Esophageal Cancer
A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.
This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the safety and effect of anti-PD-L1 antibody (ZKAB001) in neoadjuvant chemotherapy of esophageal squamous carcinoma in combination with…
- Trial name
- NCT04460066
- Testing
- anti-PD-L1 antibody, albumin bound paclitaxel, cisplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lee's Pharmaceutical Limited
AL Amyloidosis
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab
- Trial name
- NCT06649695
- Testing
- Teclistamab
- Where
- 9 sites in Australia, France and 4 more
- Volunteers
- 30 people
- Sponsor
- European Myeloma Network B.V.
Recurrent Adult Hodgkin Lymphoma
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
This phase I clinical trial studies the side effects and best dose of radiolabeled monoclonal antibody therapy when given together with combination chemotherapy before stem cell transplant and to see how well it works in treating…
- Trial name
- NCT01476839
- Testing
- basiliximab, carmustine, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.